Mark F Brady
3PUBLICATIONS
29CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (3)
Sort by Publication Date:
|Oct 03, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.Jung-Min Lee, Mark F Brady, Austin Miller
|Jun 27, 2022
Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study.Larry J Copeland, Mark F Brady, Robert A Burger
|Mar 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial.Joyce F Liu, Mark F Brady, Ursula A Matulonis
Pageof 1
Frequent Collaborators
2 joint publications
Austin Miller
2 joint publications
David Cella
2 joint publications
Angeles Alvarez Secord
2 joint publications
Michael A Bookman
1 joint publications
Joyce F Liu
1 joint publications
Ursula A Matulonis
1 joint publications
William P Tew
1 joint publications
Melissa A Geller
1 joint publications
Keiichi Fujiwara
1 joint publications
Michael Carney
